Skip to main content

Galsulfase

Medically reviewed by Drugs.com. Last updated on Jul 14, 2023.

Pronunciation

(gal SUL fase)

Index Terms

Dosage Forms

Excipient information presented when available (limited, particularly for generics); consult specific product labeling.

Solution, Intravenous [preservative free]:

Naglazyme: 1 mg/mL (5 mL) [contains mouse (murine) and/or hamster protein, polysorbate 80]

Brand Names: U.S.

Pharmacologic Category

Pharmacology

Galsulfase is a recombinant form of N-acetylgalactosamine 4-sulfatase, produced in Chinese hamster cells. A deficiency of this enzyme leads to accumulation of the glycosaminoglycan dermatan sulfate in various tissues, causing progressive disease which includes decreased growth, skeletal deformities, upper airway obstruction, clouding of the cornea, heart disease, and coarse facial features. Exogenous replacement of this enzyme has been shown to improve mobility and physical function (measured by walking and stair-climbing).

Distribution

Vz: Week 1: 103 mL/kg (range: 56 to 323 mL/kg); Week 24: 69 mL/kg (range: 59 to 2,799 mL/kg)

Half-Life Elimination

Week 1: Median 9 minutes (range: 6 to 21 minutes); Week 24: Median 26 minutes (range: 8 to 40 minutes)

Use: Labeled Indications

Mucopolysaccharidosis VI: Replacement therapy in patients with mucopolysaccharidosis VI (MPS VI; Maroteaux-Lamy syndrome) to improve walking and stair-climbing capacity.

Contraindications

There are no contraindications listed in the manufacturer's labeling

Dosing: Adult

Note: Premedicate with antihistamines with/without antipyretics 30 to 60 minutes prior to the start of the infusion.

Mucopolysaccharidosis VI (MPS VI): IV: 1 mg/kg once weekly

Dosing: Pediatric

Mucopolysaccharidosis (MPS) VI: Note: Premedicate with antihistamines with or without antipyretics 30 to 60 minutes prior to infusion.

Infants: Limited data available: IV: 1 or 2 mg/kg/dose once weekly has been used in four infants (3 to 12 months); similar safety results to those of older patients were reported (Harmatz 2014)

Children and Adolescents: IV: 1 mg/kg/dose once weekly

Reconstitution

After calculating dose, round to the nearest whole vial to prepare infusion. Dilute in NS to a final volume of 250 mL (including volume of galsulfase). Slowly add galsulfase to infusion bag (use a low-protein binding container; compatibility in glass containers has not been studied). For patients with fluid restriction, the dose may be added to 100 mL NS (total volume is 100 mL is not necessary). Gently rotate bag to distribute. Do not shake or agitate, do not use filter needle.

Administration

IV: Infuse over at least 4 hours; infusions of a 250 mL total volume should begin at a rate of 6 mL/hour for the first hour, if tolerated, may increase the rate of infusion to 80 mL/hour for the remaining 3 hours. May extend infusion time up to 20 hours if infusion reactions occur. For patients requiring fluid restriction, solutions of 100 mL may be used with the rate adjusted to infuse over at least 4 hours. Administer using infusion pump and PVC (low protein-binding) infusion set with in-line low protein-binding 0.2 micrometer filter.

Premedicate with antihistamines (with or without antipyretics) 30 to 60 minutes prior to infusion. In case of infusion-related reactions, decrease infusion rate or temporarily discontinue. Discontinue immediately if severe reaction occurs. Patients requiring supplemental oxygen or CPAP during sleep should have these treatments readily available in case of infusion-related or antihistamine-induced reaction.

Storage

Prior to reconstitution, store intact vials at 2°C to 8°C (36°F to 46°F). Do not freeze. Do not shake. Protect from light. Following dilution in NS, use immediately. May store under refrigeration if used within 48 hours from the time of preparation to the completion of infusion. Do not store solution for infusion at room temperature. Allow vials to reach room temperature prior to dilution. Do not keep vials at room temperature >24 hours prior to dilution. Do not heat or microwave vials.

Drug Interactions

There are no known significant interactions.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

Note: Percentages reported are from a placebo-controlled study (39 patients, 19 on galsulfase); also included are adverse effects noted during other clinical studies.

Cardiovascular: Chest pain (16%), hypertension (11%)

Central nervous system: Pain (32%), chills (21%), absent reflexes (11%), malaise (11%), headache

Dermatologic: Skin rash (21%), pruritus, urticaria

Gastrointestinal: Abdominal pain (47%), gastroenteritis (11%), nausea, vomiting

Hypersensitivity: Angioedema

Neuromuscular & skeletal: Arthralgia (42%)

Ophthalmic: Conjunctivitis (21%), corneal opacity (increased, 11%)

Otic: Otalgia (42%), auditory impairment (11%)

Respiratory: Dyspnea (21%), pharyngitis (11%), nasal congestion (11%), apnea, laryngeal edema, respiratory distress

Miscellaneous: Antibody development (98%), infusion related reaction (56%), umbilical hernia (11%), fever

<1%, postmarketing, and/or case reports: Anaphylaxis, bradycardia, bronchospasm, cyanosis, erythema, hypotension, hypoxia, pallor, paresthesia, renal disease (membranous), respiratory failure, shock, spinal cord compression, tachycardia, tachypnea, thrombocytopenia

Warnings/Precautions

Concerns related to adverse effects:

• Hypersensitivity: Severe hypersensitivity reactions, including anaphylaxis, severe allergic reactions, shock, respiratory distress, dyspnea, bronchospasm, laryngeal edema, and hypotension have been reported during and within 24 hours after infusion. Immediate treatment for hypersensitivity reactions should be available during administration. Discontinue treatment immediately if signs or symptoms of anaphylaxis or severe allergic reactions occur; use caution upon rechallenge.

• Immune-mediated reactions: Severe type III immune-mediated reactions (eg, membranous glomerulonephritis) have occurred; monitor patients closely. Consider discontinuation of treatment if signs or symptoms occur; use caution with readministration (some patients have been successfully re-challenged with close supervision).

• Infusion reactions: Infusion-related reactions have been commonly reported; may be sporadic and/or severe. Serious/severe infusion reactions have included laryngeal edema, apnea, respiratory distress, dyspnea, angioedema, and anaphylactoid reaction, pyrexia, chest pain, rash, urticaria, and conjunctivitis; other reactions included chills, nausea, vomiting, pruritus, erythema, abdominal pain, hypertension, hypotension, headache, tremor, and cough. Reactions began as early as week 1 and as late as week 146 of treatment. Many patients experienced recurrent infusion reactions during multiple infusions, though not always in consecutive weeks. Patients should be premedicated with antihistamines and/or antipyretics prior to infusion; evaluate airway prior to therapy (due to possible effects of antihistamine use). Symptoms typically abated with slowing or temporary interruption of the infusion and administration of additional antihistamines, antipyretics, and, occasionally, corticosteroids. Most patients were able to complete their infusions. Subsequent infusions were managed with a slower rate of administration, treatment with additional prophylactic antihistamines, and, in the event of a more severe reaction, treatment with prophylactic corticosteroids. Discontinue treatment immediately and initiate appropriate treatment if severe reaction occurs; use caution with readministration (consider the risks/benefits of readministering following a severe reaction).

Disease-related concerns:

• Acute febrile/respiratory illness: Consider delaying treatment in patients with an acute febrile or respiratory illness.

• Patients at risk for fluid overload: Use with caution in patients who are at risk of fluid overload (patients ≤20 kg, underlying respiratory disease, or compromised cardiopulmonary function); may cause heart failure. Monitor patients closely.

• Sleep apnea: Use with caution in patients with sleep apnea (sleep apnea is common in patients with MPS VI); antihistamine pretreatment may increase the risk of apneic episodes. Evaluate airway patency prior to initiation of treatment; apnea treatment options should be readily available during the infusion and with antihistamine premedication.

• Spinal/cervical cord compression: Worsening and new-onset spinal/cervical cord compression (SCC) has been reported (SCC with resultant myelopathy is a known and anticipated serious complication of MPS VI). Monitor patients for signs and symptoms of SCC (eg, back pain, limb paralysis below the level of compression, urinary and fecal incontinence) and provide appropriate clinical care.

Special populations:

• Adults: Studies did not include patients >29 years of age.

Dosage form specific issues:

• Polysorbate 80: Some dosage forms may contain polysorbate 80 (also known as Tweens). Hypersensitivity reactions, usually a delayed reaction, have been reported following exposure to pharmaceutical products containing polysorbate 80 in certain individuals (Isaksson 2002; Lucente 2000; Shelley 1995). Thrombocytopenia, ascites, pulmonary deterioration, and renal and hepatic failure have been reported in premature neonates after receiving parenteral products containing polysorbate 80 (Alade 1986; CDC 1984). See manufacturer's labeling.

Monitoring Parameters

Monitor for infusion/hypersensitivity reactions; signs and symptoms of spinal/cervical cord compression.

Pregnancy Considerations

Information related to the use of galsulfase in pregnancy is limited (Stewart 2016).

Pregnancy may exacerbate symptoms of mucopolysaccharidosis VI, leading to adverse maternal and fetal outcomes.

Patient Education

What is this drug used for?

• It is used to treat mucopolysaccharidosis VI.

All drugs may cause side effects. However, many people have no side effects or only have minor side effects. Call your doctor or get medical help if any of these side effects or any other side effects bother you or do not go away:

• Abdominal pain

• Joint pain

• Ear pain

• Cough

• Nausea

• Vomiting

• Throat irritation

• Nose irritation

• Loss of strength and energy

WARNING/CAUTION: Even though it may be rare, some people may have very bad and sometimes deadly side effects when taking a drug. Tell your doctor or get medical help right away if you have any of the following signs or symptoms that may be related to a very bad side effect:

• Kidney problems like unable to pass urine, blood in the urine, change in amount of urine passed, or weight gain.

• Shortness of breath

• Excessive weight gain

• Severe dizziness

• Passing out

• Chest pain

• Severe headache

• Chills

• Vision changes

• Change in hearing

• Eye pain

• Severe eye irritation

• Trouble moving

• Back pain

• Urinary or leaking of stool

• Swelling of arms or legs

• Tremors

• Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing, swallowing, or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.

Note: This is not a comprehensive list of all side effects. Talk to your doctor if you have questions.

Consumer Information Use and Disclaimer: This information should not be used to decide whether or not to take this medicine or any other medicine. Only the healthcare provider has the knowledge and training to decide which medicines are right for a specific patient. This information does not endorse any medicine as safe, effective, or approved for treating any patient or health condition. This is only a limited summary of general information about the medicine’s uses from the patient education leaflet and is not intended to be comprehensive. This limited summary does NOT include all information available about the possible uses, directions, warnings, precautions, interactions, adverse effects, or risks that may apply to this medicine. This information is not intended to provide medical advice, diagnosis or treatment and does not replace information you receive from the healthcare provider. For a more detailed summary of information about the risks and benefits of using this medicine, please speak with your healthcare provider and review the entire patient education leaflet.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.